KR20230069941A - 리비톨 치료 - Google Patents

리비톨 치료 Download PDF

Info

Publication number
KR20230069941A
KR20230069941A KR1020237010497A KR20237010497A KR20230069941A KR 20230069941 A KR20230069941 A KR 20230069941A KR 1020237010497 A KR1020237010497 A KR 1020237010497A KR 20237010497 A KR20237010497 A KR 20237010497A KR 20230069941 A KR20230069941 A KR 20230069941A
Authority
KR
South Korea
Prior art keywords
day
ribitol
dose
comprises administering
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010497A
Other languages
English (en)
Korean (ko)
Inventor
치 롱 루
보 우
Original Assignee
더 샬럿 멕클렌버그 하스피털 오소러티 디/비/에이 에이트리엄 헬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 샬럿 멕클렌버그 하스피털 오소러티 디/비/에이 에이트리엄 헬스 filed Critical 더 샬럿 멕클렌버그 하스피털 오소러티 디/비/에이 에이트리엄 헬스
Publication of KR20230069941A publication Critical patent/KR20230069941A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Molecular Biology (AREA)
KR1020237010497A 2020-09-10 2021-09-09 리비톨 치료 Pending KR20230069941A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076761P 2020-09-10 2020-09-10
US63/076,761 2020-09-10
PCT/US2021/049677 WO2022056137A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Publications (1)

Publication Number Publication Date
KR20230069941A true KR20230069941A (ko) 2023-05-19

Family

ID=80629815

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010497A Pending KR20230069941A (ko) 2020-09-10 2021-09-09 리비톨 치료

Country Status (10)

Country Link
US (1) US20230364118A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210708A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023544249A (cg-RX-API-DMAC7.html)
KR (1) KR20230069941A (cg-RX-API-DMAC7.html)
CN (1) CN117355310A (cg-RX-API-DMAC7.html)
AU (1) AU2021338706A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191582A1 (cg-RX-API-DMAC7.html)
IL (1) IL301088A (cg-RX-API-DMAC7.html)
MX (1) MX2023001881A (cg-RX-API-DMAC7.html)
WO (1) WO2022056137A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
CN114269712A (zh) 2019-05-28 2022-04-01 夏洛特-梅克伦堡医院管理局D/B/A艾奇恩健康 制备核糖醇的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245235B2 (en) * 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
WO2020041750A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Also Published As

Publication number Publication date
AU2021338706A1 (en) 2023-05-25
WO2022056137A1 (en) 2022-03-17
US20230364118A1 (en) 2023-11-16
EP4210708A4 (en) 2024-10-23
WO2022056137A9 (en) 2022-04-14
JP2023544249A (ja) 2023-10-23
CA3191582A1 (en) 2022-03-17
CN117355310A (zh) 2024-01-05
MX2023001881A (es) 2023-04-03
IL301088A (en) 2023-05-01
EP4210708A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
US11690812B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
JP6612370B2 (ja) ポンペ病の処置のための投与計画
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びsglt2阻害薬を含む医薬組成物
CZ295567B6 (cs) Tetrahydrolipstatin pro výrobu orálního farmaceutického prostředku pro ošetřování typu II diabetes mellitus
TW200808324A (en) Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
US20210338648A1 (en) Methods and compositions for reducing serum uric acid
EP3065725A2 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
US20120289565A1 (en) Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
EP2034992A2 (en) Method of improved diuresis in individuals with impaired renal function
JP2020523334A (ja) 過活動膀胱の治療のためのビベグロンの投薬
US20230364118A1 (en) Ribitol treatment
AU2019354784A1 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
US20200061092A1 (en) Methods and compositions for treating disorders associated with muscle weakness
WO2012154779A1 (en) Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
WO2025212841A1 (en) Compositions and methods for treating diseases and disorders associated with muscle weakness
TW202539703A (zh) 治療多囊性腎病之方法
KR20200026975A (ko) 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
RU2653478C2 (ru) Способ улучшения функции печени
CN116113408B (zh) 治疗慢性肾病的方法和药物组合物
WO2012154892A1 (en) Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
US20140194454A1 (en) Combinations of trospium and salivary stimulants for the treatment of overactive bladder
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための1h-1,2,3-トリアゾール-4-カルボン酸
HK40114255A (en) Use of vibegron to treat overactive bladder
EP2767287B1 (en) Agent for preventing or treating htlv-i associated myelopathy
WO2012154778A1 (en) Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230327

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240830

Comment text: Request for Examination of Application